Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P15088 (mast cell)
 14,925 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Repeated intraperitoneal administration of compound 48/80 to rats produced gastric lesions, a decrease in connective tissue mast cells (CTMCs) and an increase in gastric mucosal mast cells (MMCs). The ratio of MMC to CTMC was significantly correlated with lesion formation. A mast cell stabilizer, MAR-99 (50 mg/kg), prevented lesion formation and changes in the mast cells. Omeprazole (20 or 60 mg/kg) significantly reduced the gastric lesions, but mast cell changes persisted. Cimetidine (50 mg/kg) could not inhibit compound 48/80-induced lesions nor a decrease in CTMCs, but did prevent an increase in MMCs. These facts suggest that in compound 48/80-induced gastric lesions chemical mediators released from CTMCs might be trigger factors, while intraluminal gastric acid might be an aggravating factor. Furthermore, the increase in MMCs might be regulated by histamine released from the CTMCs via H2 receptors and have no causal relation to lesions formation.
 ...
PMID:Histological evaluation of mast cells in rat gastric mucosal lesions induced by compound 48/80. 280 59

A 12-year-old, female 5q- syndrome case of refractory anemia with excess of blasts in transformation (RAEB-T) evolving to mast cell leukemia is described. This case was admitted because of general fatigue, when her peripheral blood count revealed anemia and leukocytosis with basophil-like cells. RAEB-T was diagnosed based on the laboratory findings of her peripheral blood and bone marrow aspiration, which revealed over 10% peripheral blast cells and dysmyelopoietic changes in all three lineages. Chromosomal analysis of the bone marrow cells showed 46, XX, 5q-. Six months later, the RAEB-T phase evolved to acute leukemia, despite prednisolone, vitamin D3, oxymetholone and low-dose cytosine arabinoside treatment. She had remarkable pancytopenia, hemorrhage, and hepatosplenomegaly, which were not responsive to daunomycin, enocitabine, etoposide, and 6-mercaptopurine, and eventually died. This case was unique in that her karyotype changed to normal; 46, XX, and her blast cells were mast cell lineage during the overt leukemic phase. Interestingly, some blasts were intermediate cells possessing the ultrastructural features typical of both basophils and mast cells.
 ...
PMID:[Mast cell leukemia evolved from RAEB-T (5q-syndrome) in a 12 year-old girl]. 869 90

To clarify the anti-gastric acid secretory mechanism of 1,6-dihydro-2-[2-(2-methylpropoxy)anilino]-6-oxo-5-pyrimidinecarbo xylic acid (CAS 98772-05-5, MAR-99), the relationship between gastric acid secretion and gastric mucosal mast cell (MMC) was studied and the effect of this compound on these parameters was examined and compared with anti-allergic drugs (mast cell stabilizers) and anti-ulcer drugs. The release of histamine from MMC cultured from bone marrow and connective tissue mast cell (CTMC) isolated from peritoneal cavity was found to be induced by the addition of ethanol (final conc. 17.5%), and the inhibitory effect on histamine release from MMC is closely associated with the anti-gastric secretory effect. That is to say, MAR-99 (10(-9)-10(-7) mol/l) inhibited histamine release from MMC induced by ethanol in a concentration-dependent manner. The action of MAR-99 on MMC was more sensitive than that of CTMC. In addition, MAR-99 (100 mg/kg i.d.) suppressed gastric acid secretion. On the other hand, anti-allergic drugs (mast cell stabilizers), such as DSCG and tranilast (both 10(-7) mol/l), markedly inhibited histamine release from CTMC induced by ethanol, but these drugs (10(-8)-10(-7) mol/l) showed only a tendency to prevent the release of histamine from MMC. Furthermore these drugs (both 100 mg/ kg i.d.) had no effects on gastric acid secretion. Equally anti-ulcer drugs, such as cetraxate, teprenone and sofalcone, had no effects on histamine release from mast cells of two types and gastric acid secretion. From these results, it was suggested that MMC is closely correlated with gastric acid secretion, and the anti-gastric secretory effect of MAR-99 may mainly contribute to prevent the degranulation of MMC.
 ...
PMID:Anti-gastric acid secretory mechanism of 1,6-dihydro-2-[2-(2-methylpropoxy)anilino]-6-oxo-5-pyrimidinecarboxylic acid. Effect on mucosal mast cell. 887 42

The aim of this study is to define the putative role of complement activation and mucosal mast cell (MMC) degranulation in the pathogenesis of rapid ischemia-reperfusion (I/R) injury. We prepared complement activity-depleted rats by the administration of the anti-complementary agent K-76COONa. To assess the role of MMC degranulation, we used the MMC stabilizer MAR-99 and genetically mast cell-deficient Ws/Ws rats. Autoperfused segments of the jejunum were exposed to 60 min of ischemia, followed by 60 min reperfusion. The epithelial permeability was assessed by (51)Cr-EDTA clearance rate, and the number of MMC was immunohistochemically assessed. I/R treatment induced a marked increase in mucosal permeability and MMC degranulation. The treatment with K-76COONa and MAR-99 significantly attenuated these changes. Furthermore, in Ws/Ws rats the increase in mucosal permeability and MMC degranulation was significantly attenuated. These findings indicate the role of complement activation and MMC activation in the pathogenesis of rapid intestinal I/R injury. A regulation of the complement activation and MMC degranulation may be one of the clinical strategies for prevention of I/R-induced mucosal injury.
 ...
PMID:Role of complement activation and mast cell degranulation in the pathogenesis of rapid intestinal ischemia/reperfusion injury in rats. 1117 19